Research Information System
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.113, 2025 (SCI-Expanded)
The present study investigates the development of dual-targeted immunoliposomes for improved therapeutic delivery of oxaliplatin in HER2-overexpressing gastric cancer. Liposomal formulations encapsulating oxaliplatin were conjugated with trastuzumab and iRGD peptide for targeted tumor delivery. Physicochemical characterization, in vitro cellular uptake, cytotoxicity, apoptosis induction, and in vivo targeting efficacy were systematically evaluated. Results revealed that HER2-targeted immunoliposomes have optimal encapsulation efficiency (similar to 22 %), appropriate nanoparticle size (271.3 +/- 4.3 nm), zeta potential (-33.5 +/- 0.8 mV), sustained drug release, and enhanced stability. Dual-targeted liposomes demonstrated significantly improved cytotoxicity, enhanced cellular uptake, and pronounced apoptosis induction in HER2-positive gastric cancer cells compared to untargeted oxaliplatin liposomes. Biodistribution studies indicated substantial tumor accumulation, which correlated with enhanced antitumor efficacy and reduced systemic toxicity in vivo. Thus, the present study substantiates dual-targeted liposomes as a promising delivery platform for improving oxaliplatin efficacy in targeted gastric cancer therapy.